IL23R
Overview
IL23R (Interleukin 23 Receptor) encodes a receptor for interleukin 23 involved in immune signaling. In cancer genomics, IL23R has been identified as a fusion partner in pediatric inflammatory myofibroblastic tumor, where gene fusions involving IL23R activate JAK-STAT signaling and confer therapeutic sensitivity to JAK inhibitors.
Alterations observed in the corpus
- VCAN–IL23R fusion gene identified in pediatric inflammatory myofibroblastic tumor (IMT), serving as a JAK-inhibitor target with documented treatment response PMID:28007021.
Cancer types (linked)
- Inflammatory myofibroblastic tumor (IMT): VCAN–IL23R fusion drives JAK-STAT activation and was identified as a therapeutic target in pediatric sequencing PMID:28007021.
Co-occurrence and mutual exclusivity
- No co-occurrence data reported in the current corpus.
Therapeutic relevance
- VCAN–IL23R fusion is a JAK-inhibitor target; treatment response was documented in a pediatric patient with inflammatory myofibroblastic tumor PMID:28007021.
Open questions
- Broader prevalence of VCAN–IL23R or other IL23R fusions in IMT and related tumors requires characterization in larger cohorts.
Sources
This page was processed by crosslinker on 2026-05-14.